Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant IMRT with concurrent raltitrexed for locally advanced gastric cancer after D0/D1 surgery
ChiCTR-ONC-17010450Phase 2Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Zhongnan Hospital of Wuhan University. Primary endpoints: Acute toxic reaction and Chronic toxic reaction. Started Jan 2017; status: recruiting.
02
Drugs
raltitrexed
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-ONC-17010450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-17010450.